Theranostic Applications of Nanomaterials in the Field of Cardiovascular Diseases-Reference-Cited by-同舟云学术

Theranostic Applications of Nanomaterials in the Field of Cardiovascular Diseases

Published:2022-01 Issue:2 Volume:28 Page:91-103
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

Sahoo Rakesh K.¹,Singh Himani¹,Thakur Kamlesh¹,Gupta Umesh¹,Goyal Amit K .¹

Affiliation:

1. Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandarsindri, Ajmer, Rajasthan 305817, India

Abstract

: A large percentage of people are being exposed to mortality due to cardiovascular diseases. Convention approaches have not provided satisfactory outcomes in the management of these diseases. To overcome the limitations of conventional approaches, nanomaterials like nanoparticles, nanotubes, micelles, lipid-based nanocarriers, dendrimers, and carbon-based nanoformulations represent the new aspect of diagnosis and treatment of cardiovascular diseases. The unique inherent properties of the nanomaterials are the major reasons for their rapidly growing demand in the field of medicine. Profound knowledge in the field of nanotechnology and biomedicine is needed for the notable translation of nanomaterials into theranostic cardiovascular applications. In this review, the authors have summarized different nanomaterials which are being extensively used to diagnose and treat the diseases, such as coronary heart disease, myocardial infarction, atherosclerosis, stroke and thrombosis.

Funder

DST FIST to Department of Pharmacy, Central University of Rajasthan

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Reference153 articles.

1. Behera S.S.; Pramanik K.; Nayak M.K.; Recent advancement in the treatment of cardiovascular diseases: Conventional therapy to nanotechnology. Curr Pharm Des 2015,21(30),4479-4497

2. Cai H.; Harrison D.G.; Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000,87(10),840-844

3. Lim S.S.; Vos T.; Flaxman A.D.; Danaei G.; Shibuya K.; Adair-Rohani H.; Amann M.; Anderson H.R.; Andrews K.G.; Aryee M.; Atkinson C.; Bacchus L.J.; Bahalim A.N.; Balakrishnan K.; Balmes J.; Barker-Collo S.; Baxter A.; Bell M.L.; Blore J.D.; Blyth F.; Bonner C.; Borges G.; Bourne R.; Boussinesq M.; Brauer M.; Brooks P.; Bruce N.G.; Brunekreef B.; Bryan-Hancock C.; Bucello C.; Buchbinder R.; Bull F.; Burnett R.T.; Byers T.E.; Calabria B.; Carapetis J.; Carnahan E.; Chafe Z.; Charlson F.; Chen H.; Chen J.S.; Cheng A.T.; Child J.C.; Cohen A.; Colson K.E.; Cowie B.C.; Darby S.; Darling S.; Davis A.; Degenhardt L.; Dentener F.; Des Jarlais D.C.; Devries K.; Dherani M.; Ding E.L.; Dorsey E.R.; Driscoll T.; Edmond K.; Ali S.E.; Engell R.E.; Erwin P.J.; Fahimi S.; Falder G.; Farzadfar F.; Ferrari A.; Finucane M.M.; Flaxman S.; Fowkes F.G.; Freedman G.; Freeman M.K.; Gakidou E.; Ghosh S.; Giovannucci E.; Gmel G.; Graham K.; Grainger R.; Grant B.; Gunnell D.; Gutierrez H.R.; Hall W.; Hoek H.W.; Hogan A.; Hosgood H.D.; Hoy D.; Hu H.; Hubbell B.J.; Hutchings S.J.; Ibeanusi S.E.; Jacklyn G.L.; Jasrasaria R.; Jonas J.B.; Kan H.; Kanis J.A.; Kassebaum N.; Kawakami N.; Khang Y.H.; Khatibzadeh S.; Khoo J.P.; Kok C.; Laden F.; Lalloo R.; Lan Q.; Lathlean T.; Leasher J.L.; Leigh J.; Li Y.; Lin J.K.; Lipshultz S.E.; London S.; Lozano R.; Lu Y.; Mak J.; Malekzadeh R.; Mallinger L.; Marcenes W.; March L.; Marks R.; Martin R.; McGale P.; McGrath J.; Mehta S.; Mensah G.A.; Merriman T.R.; Micha R.; Michaud C.; Mishra V.; Mohd Hanafiah K.; Mokdad A.A.; Morawska L.; Mozaffarian D.; Murphy T.; Naghavi M.; Neal B.; Nelson P.K.; Nolla J.M.; Norman R.; Olives C.; Omer S.B.; Orchard J.; Osborne R.; Ostro B.; Page A.; Pandey K.D.; Parry C.D.; Passmore E.; Patra J.; Pearce N.; Pelizzari P.M.; Petzold M.; Phillips M.R.; Pope D.; Pope C.A.; Powles J.; Rao M.; Razavi H.; Rehfuess E.A.; Rehm J.T.; Ritz B.; Rivara F.P.; Roberts T.; Robinson C.; Rodriguez-Portales J.A.; Romieu I.; Room R.; Rosenfeld L.C.; Roy A.; Rushton L.; Salomon J.A.; Sampson U.; Sanchez-Riera L.; Sanman E.; Sapkota A.; Seedat S.; Shi P.; Shield K.; Shivakoti R.; Singh G.M.; Sleet D.A.; Smith E.; Smith K.R.; Stapelberg N.J.; Steenland K.; Stöckl H.; Stovner L.J.; Straif K.; Straney L.; Thurston G.D.; Tran J.H.; Van Dingenen R.; van Donkelaar A.; Veerman J.L.; Vijayakumar L.; Weintraub R.; Weissman M.M.; White R.A.; Whiteford H.; Wiersma S.T.; Wilkinson J.D.; Williams H.C.; Williams W.; Wilson N.; Woolf A.D.; Yip P.; Zielinski J.M.; Lopez A.D.; Murray C.J.; Ezzati M.; AlMazroa M.A.; Memish Z.A.; A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012,380(9859),2224-2260

4. Yusuf S.; Reddy S.; Ounpuu S.; Anand S.; Global burden of cardiovascular diseases: Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001,104(22),2746-2753

5. Bae S.; Kim S.R.; Kim M.N.; Shim W.J.; Park S.M.; Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: A systematic review and meta-analysis. Heart 2021,107(5),373-380

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyaluronic acid-modified mesoporous silica nanoprobes for target identification of atherosclerosis;Biochemical and Biophysical Research Communications;2024-02

2. Nanomaterials Responsive to Endogenous Biomarkers for Cardiovascular Disease Theranostics;Advanced Functional Materials;2023-03-31

3. Harnessing nanotechnology for cardiovascular disease applications - a comprehensive review based on bibliometric analysis;Nano Today;2022-06